2nd Advanced Practice Provider Hybrid Symposium
Presented by ibdhorizons
- 8:15 - 9:00
- Goals of Therapy in IBD: Where are we today?
- 10 Minute Presentation followed by a Panel Discussion with 2 other speakers.
Speakers:Ghassan Wahbeh-- MD
- 9:00 - 9:45
- Monitoring Disease Activity: Why & How
Speakers:Karlee Ausk-- MD
- 9:45 - 10:15
- 10:15 - 11:00
- Family Planning, Pregnancy, and IBD Management
- 11:45 - 12:30
- 12:30 - 13:15
- Infection Risk in IBD: Focus on COVID-19
Speakers:Jeffrey Jacobs-- MD
- 13:15 - 14:00
- Clinical Models of IBD Care: Eye on Telemedicine
Speakers:Mitra Barahimi-- MD
- 14:00 - 14:45
- Approach to the Symptomatic IBD Patient in Endoscopic
Speakers:David Suskind-- MD
- 14:45 - 15:20
- Skin Manifestations of IBD and IBD-therapy
Speakers:Anita Afzali-- MD-- MPH-- MHCM
We would like to extend a very special thank you to our sponsors for their support of our 6th Annual Pacific Northwest Symposium.
- 1 Day – Novel multiplatform in-person & virtual attendance covering the Pacific Northwest region with an estimated 200 attendees.
- In-person attendance will be limited to meet the highest safety standards. A complete virtual conference platform will be offered exclusively if in-person attendance cannot be safely conducted.
- Format will include a series of IBD-focused presentations, panel discussions, and case studies with dynamic attendee participation using audience interactive technology.
This activity was developed for nurse practitioners, physician assistants, gastroenterology registered nurses, clinical nurse specialists, pharmacists, dietitians, medical assistants, physicians, and family practitioners involved in the care of patients with IBD.
At the conclusion of this learning activity, participants will do the following:
- Outline the goals of IBD care and incorporate the latest concepts, including treat-to-target in IBD clinical practice to maximize patient outcomes.
- Appraise the available non-invasive testing (including blood, stool tests, and imaging modalities) to evaluate for disease activity in IBD and interpret these studies relative to other objective markers of disease such as endoscopy.
- Assess current knowledge on infection risk in IBD, including COVID-19, and the implications on managing IBD patients, especially during the current pandemic, including the risk of complications, interrupting therapy, and vaccination guidelines.
- Review the common dermatologic extraintestinal manifestations in IBD (related to disease, therapy, or complications) and apply a practical approach to screen and intervene as needed.
- Review the causes of active symptoms in IBD patients in clinical remission and apply a practical approach to diagnose and manage GI symptoms in the absence of active inflammation.
- Appraise the available telemedicine models of health care delivery with their advantages and limitations and apply this knowledge to enhance equitable IBD patient care access and outcomes, especially for underserved populations.
- Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
- Discuss the newly approved and soon-to-be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.